Medical Information
France
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you

This content is intended for French Healthcare Professionals. Would you like to proceed?

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

The European Medicines Agency has issued a conditional Marketing Authorisation to permit the use of COMIRNATY COVID-19 mRNA vaccine (tozinameran).

Comirnaty COVID-19 mRNA Vaccine (tozinameran)

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

Comirnaty COVID-19 mRNA Vaccine Quick Search

After its recent approval by the EMA, the last version of the Summary of Product Characteristics (SPC) for COMIRNATY formulation to be diluted for adult and adolescent ≥12 years (30 μg/dose; purple cap) is available here. The last SPC of COMIRNATY pediatric formulation for 5-11 years (10 μg/dose; orange cap) is available here. The last SPC for COMIRNATY pre-filled formulation for adult and adolescent ≥12 years (30 μg/dose; grey cap) is available here. The SPC will be available soon on the French Public database of medications.

Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
Report Adverse Event